Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More
The follow on study involves assessing of PF708 vs Forteo in 102 patients including 52 with osteoporosis and 50 with caregivers The study demonstrated PF708 had fewer or equal user errors showing 33% and 17 % of critical tasks respectively further concluded that the study data of user interface of the FDA-approved PF708 product is […]Read More
Shots: The US FDA has granted approval to PF708, a biosimilar of Eli Lilly’s Forteo (teriparatide injection) under the 505(b)(2) regulatory pathway for the treatment of osteoporosis in certain patients at high risk for fracture Pfenex will receive a $2.5M milestone from Alvogen on its approval in the US. The PF708 is the first approved […]Read More
Shots: Pfenex and Alvogen announce that EMA has accepted MAA for its PF708, a biosimilar to Eli Lilly’s Forsteo which has generated $289M in EU & $1.6B globally in 2018 for the treatment of osteoporosis is expected to receive marketing authorization in all 28 states of EU, as well as in Iceland, Liechtenstein and Norway, […]Read More
Shots: Pfenex to receive $2.5M as upfront and milestones for EU & MENA, milestones for ROW & 60% profit split on sales. Alvogen’s subsidiary Theramex & SAJA to get rights to develop and commercialize in EU, Switzerland & MENA respectively (Ex-Mainland China, Hong Kong, Singapore, Malaysia and Thailand) undisclosed in ROW On 11 Jun,2018 Pfenex […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
